Submit An Article

ASX:OSL

Home
ASX:OSL

Most Read
Latest Comments

Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
- Review
- January 10, 2023
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
- Review
- June 9, 2022
PharmAust completes dosing first cohort for MND treatment, patients respond positively
- Review
- January 6, 2023
Is this the most hated company on the ASX?
- Review
- August 16, 2019

Latest Articles

- News
OncoSil Gains Momentum in Germany as 120 Hospitals Secure Negotiation Rights
The fight against pancreatic cancer has taken a step forward in Germany, with 120 hospitals now legally entitled to negotiate funding for OncoSil Medical’s (ASX:OSL) innovative treatment device. This marks a 43% increase from the previous year and highlights growing recognition of the OncoSil™ device within the German healthcare system. German Hospitals Embrace OncoSil’s Innovation
Read More
Public
- News
OncoSil Medical strengthens board with appointment of governance expert
In a strategic move to bolster its governance and corporate strategy, OncoSil Medical Limited (ASX:OSL), a leader in pancreatic cancer treatment innovation, has today appointed Ms. Lel Smits as a Non-Executive Director. The addition of Ms. Smits, a renowned figure in corporate governance and investor relations, signals OncoSil’s commitment to enhancing its market position and
Read More
Public

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.